Who owns AEGLEA BIOTHERAPEUTICS INC?
- Ticker: SYRE
- CUSIP Number: 00773j202
Tip: Access positions for across all investors
Analyze quarterly positions in Aeglea Biotherapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv Download as ExcelTop investors of Aeglea Biotherapeutics stock
Who bought or sold AEGLEA BIOTHERAPEUTICS INC this quarter?
Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
---|---|---|---|---|---|
Perceptive Advisors | 2.6M | $56M | 3114% | Dec 2023 |
|
VR Adviser | 2.4M | $51M | 100% | Dec 2023 |
|
Commodore Capital | 1.9M | $41M | 1520% | Dec 2023 |
|
venBio Select Advisor | 1.8M | $40M | 15951% | Dec 2023 |
|
Cormorant Asset Management | 937k | $20M | 100% | Dec 2023 |
|
EcoR1 Capital | 887k | $19M | 344% | Dec 2023 |
|
Franklin Resources | 687k | $15M | 100% | Dec 2023 |
|
BVF | 687k | $15M | 100% | Dec 2023 |
|
Wellington Management Company | 636k | $14M | 112% | Dec 2023 |
|
Citadel Advisors | 577k | $12M | 494% | Dec 2023 |
|
Braidwell | 515k | $11M | 100% | Dec 2023 |
|
Global Endowment Management | 513k | $11M | 100% | Dec 2023 |
|
Fairmount Funds Management | 378k | $8.1M | 0% | Dec 2023 |
|
Boxer Capital | 250k | $5.4M | 100% | Dec 2023 |
|
Logos Global Management | 150k | $3.2M | -29% | Dec 2023 |
|
Dr. Jeffrey R. Jay, M.D. | 125k | $2.7M | 100% | Dec 2023 |
|
Millennium Management | 109k | $2.3M | 187% | Dec 2023 |
|
Assenagon Asset Management | 64k | $2.4M | 100% | Mar 2024 |
|
Barclays | 46k | $979k | 100% | Dec 2023 |
|
Vanguard Group | 39k | $849k | 19% | Dec 2023 |
|
Two Sigma Investments | 28k | $605k | 100% | Dec 2023 |
|
Cubist Systematic Strategies | 26k | $563k | 100% | Dec 2023 |
|
Marshall Wace | 20k | $436k | 100% | Dec 2023 |
|
Blackstone Group | 20k | $430k | 100% | Dec 2023 |
|
Legato Capital Management | 12k | $435k | 100% | Mar 2024 |
|
Citigroup | 10k | $222k | 100% | Dec 2023 |
|
Carlyle | 9.6k | $204k | 100% | Dec 2023 |
|
ADAR1 Capital Management | 6.4k | $139k | 100% | Dec 2023 |
|
Virtus ETF Advisers | 6.2k | $134k | 100% | Dec 2023 |
|
Bank of New York Mellon | 6.1k | $230k | 100% | Mar 2024 |
|
UBS Group | 3.7k | $80k | 100% | Dec 2023 |
|
New York State Common Retirement Fund | 365.00 | $8.0k | 100% | Dec 2023 |
|
Advisor Group Holdings | 283.00 | $6.1k | 0% | Dec 2023 |
|
IFP Advisors | 114.00 | $2.5k | 0% | Dec 2023 |
|
Jpmorgan Chase & Co | 41.00 | $882.000200 | 0% | Dec 2023 |
|
Wells Fargo & Company | 23.00 | $494.999100 | 5% | Dec 2023 |
|
Pacific Capital Wealth Advisors | 8.00 | $172.000000 | 100% | Dec 2023 |
|
Parallel Advisors | 1.00 | $22.000000 | 100% | Dec 2023 |
|
Who sold out of Aeglea Biotherapeutics?
Fund or Company Name | Date Sold | Shares Held | Valued At |
---|---|---|---|
Aisling Capital Management | Sep 2023 | 68k | $829k |
Royal Bank of Canada | Sep 2023 | 437.00 | $5.0k |